September 4, 2019

Peptide Based Infection Therapeutics Market is Expected to Reflect a Value a Bit Less than US$ 1.5 Bn by 2022

There is a need to develop novel therapeutic agents in order to fight infections. Peptide therapeutics are used to fight infectious diseases. The global peptide based infection therapeutics market is expected to grow in the future owing to factors such as cost effectiveness of peptides, higher efficacy of peptides in managing various disease indications and infections, and can be easily synthesized owing to smaller size. Moreover, few economic factors such as government policies for startup companies, increasing foreign direct investment, as well as higher investment in healthcare are also driving the global peptide based infection therapeutics market.

Request for the Report Summary:

The rising prevalence of infectious diseases has resulted in providing an impetus to the use of peptides therapeutics to treat infections. Along with this, emerging biotech and pharmaceutical companies, strong and advanced pipelines and patent expiries are few other aspects impacting the growth of the global peptide based infection therapeutics market positively. To support this, the advancements in technology and increased research and development and the rising investments in these fields have led to the growing importance of global peptide based infection therapeutics market. North America is expected to show higher attractiveness in this market.

Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective. They are used in the treatment of infections owing to their broad spectrum of activities and mechanisms. They protect the host from pathogenic microbes and are also referred to as host defense peptides owing to their functionality in protecting the immunity system and fighting against infections.

With respect to the global peptide based infection therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share by revenue and is poised to grow at a higher growth rate to register a CAGR during the period of forecast. North America shows higher market attractiveness; this growth mainly attributed to the higher investment in the healthcare industry along with rapid technological developments. Latin America and Middle East and Africa (MEA) regions show relatively slow growth rate as compared to North America region and a fairly less market share and this trend is anticipated to continue during the period of forecast, 2017 to 2022.

Request for the Sample of the Report:

The Asia-Pacific excluding Japan (APEJ) region is expected to show a rapid growth rate and is expected to register a CAGR of 8.7% during the period of forecast. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods and technologies to better the health of the patients and enhance patient outcome. Following Asia-Pacific excluding Japan (APEJ) region, Europe regions also shows good growth rate in the global peptide based infection therapeutics market.

The telaprivir segment by drug type is expected to dominate the market in terms of market share by revenue, as of 2016 and expected to show a similar trend in 2017 as well. However, the boceprevir segment grows at a higher rate during the period of forecast as compared to telaprivir yet experiences less market share by revenue comparatively. However, with the higher rate of growth throughout the forecast period, it could be a case that the domination title might shift from telaprivir to boceprivir.

The online pharmacies segment by distribution channel is anticipated to show exponential growth rate to register a CAGR of 9.2% throughout the period of forecast, 2017 to 2022. This growth can be attributed towards the increasing awareness of the online concept, its effectiveness, reliability and convenience. However, this segment, still being in its nascent phase, has less market share as compared to other segments in the distribution channel category. The online segment is also expected to experience a higher gain in the BPS by the end of 2022. The online pharmacies segment reflects the highest growth in the North America region rate as compared to other regions during the period of forecast.

Request for the Report Customization:

About Us

Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.

Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.

The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.

Contact Us

Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Tel: +353-1-4434-232
Tel: +353-1-6111-593
Email: [email protected]